(FILES) In this file photo taken on April 8, 2020 one vial of the drug Remdesivir is seen during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the new coronavirus COVID-19 pandemic. - The US Food and Drug Administration on October 22, 2020 granted full approval to the antiviral drug Remdesivir as a treatment for patients hospitalized with Covid-19, its manufacturer Gilead said, following conditional authorization granted in May. (Photo by Ulrich Perrey / POOL / AFP)